Matinas BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- Matinas BioPharma's estimated annual revenue is currently $6.4M per year.
- Matinas BioPharma's estimated revenue per employee is $155,000
Employee Data
- Matinas BioPharma has 41 Employees.
- Matinas BioPharma grew their employee count by -5% last year.
Matinas BioPharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Co-Founder and EVP | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Technology Officer | Reveal Email/Phone |
7 | Director Program Management | Reveal Email/Phone |
8 | Sr. Director, Drug Product Development | Reveal Email/Phone |
9 | Senior Director Quality Control | Reveal Email/Phone |
10 | Director QC & AD | Reveal Email/Phone |
Matinas BioPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Matinas BioPharma?
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, LYPDISO™ (MAT9001), for the treatment of cardiovascular and metabolic conditions. LYPDISO is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors. The company will soon begin enrolling LYPDISO in a confirmatory head-to-head PD study vs Vascepa, after having shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels in a previous study, with data expected in the Q42020. In addition, the Company is developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas’ proprietary lipid nano-crystal (LNC) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.
keywords:N/A
N/A
Total Funding
41
Number of Employees
$6.4M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Bedminster
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.2M | 71 | 34% | N/A |
#2 | $7.5M | 84 | 79% | $11.5M |
#3 | $13.8M | 92 | 21% | N/A |
#4 | $21.4M | 102 | 6% | N/A |
#5 | $27.1M | 123 | 12% | N/A |